Bevacizumab offers no benefit for newly diagnosed glioblastoma, MD Anderson-led study finds

The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news